机械循环支持新范式:100例Impella 5.0经验
单中心回顾性研究纳入100例急性失代偿心衰患者,经腋动脉置入Impella 5.0临时左心室辅助装置,作为恢复过渡、持久装置过渡或移植过渡。总体生存率64%,最近30例升至90%,提示该微创策略可行且经验积累后结局改善。
要点
- 腋动脉入路Impella 5.0可用于急性失代偿心衰的三种过渡策略。
- 总体生存率64%,移植过渡组81%高于恢复过渡组50%和持久装置过渡组48%。
- 最近30例总体生存率升至90%,提示学习曲线效应。
核心结论
- 微创Impella 5.0左心室辅助装置是支持急性失代偿心衰患者过渡至恢复、持久装置或心脏移植的可行策略。
研究设计与样本
- 单中心回顾性研究,利用前瞻性维护数据库,2014年1月至2018年9月纳入100例急性失代偿心衰且药物治疗失败需Impella 5.0支持的患者。
- 患者分为恢复过渡组(n=30)、持久装置过渡组(n=23)和移植过渡组(n=47),所有装置均经腋动脉置入。
主要发现
- 患者平均年龄56.7±13.2岁,男性占84%,平均左心室射血分数16%,INTERMACS 1级占57%、2级占33%。
- 恢复过渡、持久装置过渡和移植过渡组的基线左心室射血分数分别为20%、14%、15%,肌酐分别为1.0、2.0、1.6,差异均有统计学意义(P<.05)。
- 总体生存率64%,恢复过渡组50%、持久装置过渡组48%、移植过渡组81%(P=.007)。
- 最近30例患者总体生存率升至90%。
临床怎么用
- 对急性失代偿心衰且药物治疗失败的患者,可考虑经腋动脉置入Impella 5.0作为恢复、持久装置或移植的过渡。
- 移植过渡组生存率较高,恢复过渡与持久装置过渡组生存率较低,选择过渡策略时需综合评估。
- 随着经验积累,患者生存率改善,提示中心经验与患者选择的重要性。
局限性
- 单中心回顾性研究,样本量100例,结果可能受选择偏倚影响。
- 研究期间经验积累可能影响结局,最近30例生存率改善提示学习曲线效应。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Acutely decompensated heart failure presents a complicated challenge. Established temporary support measures have significant adverse effects. A minimally invasive temporary left ventricular assist device (LVAD), the Impella 5.0 (Abiomed, Danvers, MA), has been developed to support these patients. METHODS: Patients with acutely decompensated heart failure in whom medical management had failed and who required additional support using an Impella 5.0 device were evaluated from January 2014 to September 2018 at a single center in a retrospective manner using a prospectively maintained database. Patients were treated with the device as a bridge to recovery (BTR; n = 30), bridge to durable device (BTDD; n = 23), or bridge to transplantation (BTT; n = 47). All devices were placed using an axillary artery approach. Demographic features and outcomes were evaluated for each group and compared. RESULTS: A total of 100 patients underwent insertion of an axillary Impella 5.0 LVAD. Patients had an average age of 56.7 ± 13.2 years, were predominantly male (84%), and had a severely depressed left ventricular ejection fraction (average 16%), and most had an Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) profile 1 (57%) or 2 (33%) score. When divided into groups, there was no difference in age or INTERMACS score, but a statistical difference was noted in baseline left ventricular ejection fraction (20%, 14%, 15%) and creatinine level (1.0, 2.0, 1.6), in the BTR, BTDD, or BTT group, respectively (all P < .05). Survival was 64% overall, and it was 50%, 48%, and 81% for BTR, BTDD, and BTT, respectively (P = .007). Survival improved during this experience and was 90% overall in the most recent 30 patients. CONCLUSIONS: Use of this minimally invasive LVAD system is an attractive strategy to support patients with acute decompensated heart failure to recovery, durable LVAD, or heart transplantation.
引用
- Chung JS, Emerson D, Ramzy D, et al. A New Paradigm in Mechanical Circulatory Support: 100-Patient Experience. Ann Thorac Surg. 2019. PMID: 31563492. doi:10.1016/j.athoracsur.2019.08.041
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。